Nephrology News
Tolvaptan Slows Renal Function Decline in Later-Stage ADPKD
Patients with autosomal dominant polycystic kidney disease treated with tolvaptan experienced a 35% decrease in the annual rate of decline in eGFR.
By accepting you will be accessing a service provided by a third-party external to https://www.galencarepartners.com/